Stock performance snapshot

MBX Biosciences (MBX) has caught investor attention recently, with the stock showing an 8.1% move in the last day and a 14.9% gain over the past month, alongside a 1-year total return near 196%.

That kind of run, combined with a market value around US$1.53b and clinical stage programs in endocrine and metabolic disorders, puts the spotlight on how much future progress in its pipeline might already be reflected in the current share price.

The recent 1-day share price return of 8.1% and 7-day move of 14.9% come after a softer 90-day share price return of a 7.9% decline. Momentum has shifted back in a more positive direction, while the 1-year total shareholder return near 196% shows how strongly sentiment has recovered around MBX Biosciences.

If MBX has put biopharma back on your radar, it could be a good moment to broaden your watchlist and check out 35 healthcare AI stocks

With MBX Biosciences still loss making, a market value near US$1.53b and a large gap between the recent share price and analyst targets, some investors may question whether there is a buying opportunity or whether the market is already pricing in potential future growth.

Preferred Price-to-Book of 4.5x: Is it justified?

MBX Biosciences is trading on a P/B of 4.5x, which sits below the peer average but above the broader US Pharmaceuticals industry, so the market is already attaching a premium to its balance sheet.

The P/B ratio compares the company’s market value to its net assets and is often used for businesses that are not yet generating meaningful revenue or profits. For a clinical stage biopharmaceutical company with no reported revenue and a net loss of $86.669m, this kind of metric helps you see how much investors are willing to pay today for its asset base and pipeline potential.

Here, MBX’s 4.5x P/B is described as expensive relative to the US Pharmaceuticals industry average of 2.6x, which suggests investors are paying a higher multiple than is typical for the sector. At the same time, the same 4.5x P/B is labelled good value versus a 10.3x peer average, which shows the stock trades at a discount to a narrower group of comparable companies that the model uses for its peer set.

On top of that, the SWS DCF model estimates future cash flow value at $14.37 per share, compared with the last close of $34.71, so the stock is described as trading above that DCF estimate. A DCF model projects future cash flows, then discounts them back to today using a required return, which tends to be a conservative tool for loss making, R&D heavy companies where near term cash flows are limited.

Result: Price-to-book of 4.5x (OVERVALUED).

However, the company is still loss making, with a US$86.669m net loss, and relies on successful outcomes from ongoing clinical trials to support today’s valuation.

Another view: Analyst targets and DCF send mixed signals

The P/B of 4.5x paints MBX Biosciences as expensive versus the broader US Pharmaceuticals group, and our DCF model goes further by putting future cash flow value at $14.37 per share against a recent price of $34.71. This points to a stock trading well above that estimate.

At the same time, the analyst price target of $62.55 per share sits well above the current price. As a result, one model flags downside risk while another set of expectations implies considerable upside. This raises the key question: which set of assumptions do you trust more, and why?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out MBX Biosciences for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 51 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

With sentiment clearly split, it makes sense to look at the full picture yourself and see whether the current price feels justified. Act while the data is fresh in mind and review the company’s 4 important warning signs

Looking for more investment ideas?

If MBX Biosciences has sharpened your interest, do not stop here. Use the screeners below to quickly surface other opportunities that might suit your style.

• Target potential value opportunities by reviewing companies highlighted in the 51 high quality undervalued stocks.
• Prioritize resilience and sleep easier at night by checking out the 72 resilient stocks with low risk scores.
• Hunt for lesser known opportunities with strong fundamentals using the screener containing 23 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.